Drugs / Tegafur/Uracil
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01037998 Comparator | Nov 2005 → Dec 2009 | non-small cell lung carcinoma | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegafur/Uracil | “UFUR (Tegafur/Uracil) is effective agent against chemo-naïve NSCLC.” NCT01037998 ↗ |
| Known as | UFUR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01037998 ↗ |
| Route | Oral | “adding an oral anti-angiogenesis agent (UFUR)” NCT01037998 ↗ |